DDInter299 DDInter1376
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Carfilzomib {u} (Compound) binds {v} (Gene) PSMB8
Carfilzomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Carfilzomib {u} (Compound) causes {v} (Side Effect) Headache
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Carfilzomib (Compound) resembles Ritonavir (Compound)
Carfilzomib (Compound) binds PSMB8 (Gene)
Carfilzomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Carfilzomib (Compound) causes Headache (Side Effect)
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab